Research & Development
We have, since our inception, set our strategic focus on major therapeutic areas with substantial unmet medical needs.
RMB 583.9M
R&D Expenses in 2022
35%+
Research and development personnel account for
35%+
Master’s degree or above account for
World Class R&D expertise
Cutting-edge antibody and cell therapy plassforms
Global clinical development capabilities
Collaborations and partnerships in China and globally
